Description
SWOT ANALYSIS OF BRISTOL MYERS SQUIBB
Bristol Myers Squibb
Parent Company
Bristol Myers Squibb
Category
Biopharmaceuticals
Sector
Health care
Tagline/ Slogan
Together we can prevail
Bristol-Myers Squibb is a global BioPharma company focused to discover, develop and deliver innovative medicines that help patients USP prevail over serious diseases.
STP
Diseases such as cancer, cardiovascular disease, diabetes, hepatitis B, Segment HIV/AIDS, rheumatoid arthritis and psychiatric disorders
Target Group
Healthcare professionals, doctors, pharmacists
Bristol-Myers Squibb is a global BioPharma company firmly focused on its mission to discover, develop and deliver innovative medicines that Positioning help patients prevail over serious diseases.
SWOT Analysis
1.Deliver new medicines regularly 2. Provide free medications to qualifying patients with financial problems in the U.S. 3. Employ 44000 people all over world, strong global footprint 4. Corporate strategy with the acquisition of many other companies 5. String of new technologies, alliances has strengthened the brand 6. Co-development and co-commercialization agreements with Strength companies have boosted image
1.Strong dependence on working with third parties to improve and enhance abilities 2. Substantial drop in sales for two key drugs: Plavix, a blood thinner, and Pravachol, a cholesterol-lowering drug. 3. Company layoffs and post retirement plans may affect employee Weakness relations.
1. Security technologies to make packaging and products less vulnerable to counterfeiting and to secure their movement within the supply chain 2. An integrated team addresses counterfeiting, product tampering, theft and diversion issues 3. Expand access to its products through strategic acquisitions & Opportunity partnerships.
1. The company acquires biotech companies, technology and expertise and hence a threat to its culture is infused ever more deeply. 2. Counterfeit drugs and product tampering, theft or diversion represent a threat 3. Pricing pressures Threats 4. Global economic slowdown
Competition
1.AstraZeneca 2.Roche holdings 3.Novartis 4.Merck & Co. 5.Biogen Competitors 6.Teva pharmaceuticals
doc_138396820.docx
SWOT ANALYSIS OF BRISTOL MYERS SQUIBB
Bristol Myers Squibb
Parent Company
Bristol Myers Squibb
Category
Biopharmaceuticals
Sector
Health care
Tagline/ Slogan
Together we can prevail
Bristol-Myers Squibb is a global BioPharma company focused to discover, develop and deliver innovative medicines that help patients USP prevail over serious diseases.
STP
Diseases such as cancer, cardiovascular disease, diabetes, hepatitis B, Segment HIV/AIDS, rheumatoid arthritis and psychiatric disorders
Target Group
Healthcare professionals, doctors, pharmacists
Bristol-Myers Squibb is a global BioPharma company firmly focused on its mission to discover, develop and deliver innovative medicines that Positioning help patients prevail over serious diseases.
SWOT Analysis
1.Deliver new medicines regularly 2. Provide free medications to qualifying patients with financial problems in the U.S. 3. Employ 44000 people all over world, strong global footprint 4. Corporate strategy with the acquisition of many other companies 5. String of new technologies, alliances has strengthened the brand 6. Co-development and co-commercialization agreements with Strength companies have boosted image
1.Strong dependence on working with third parties to improve and enhance abilities 2. Substantial drop in sales for two key drugs: Plavix, a blood thinner, and Pravachol, a cholesterol-lowering drug. 3. Company layoffs and post retirement plans may affect employee Weakness relations.
1. Security technologies to make packaging and products less vulnerable to counterfeiting and to secure their movement within the supply chain 2. An integrated team addresses counterfeiting, product tampering, theft and diversion issues 3. Expand access to its products through strategic acquisitions & Opportunity partnerships.
1. The company acquires biotech companies, technology and expertise and hence a threat to its culture is infused ever more deeply. 2. Counterfeit drugs and product tampering, theft or diversion represent a threat 3. Pricing pressures Threats 4. Global economic slowdown
Competition
1.AstraZeneca 2.Roche holdings 3.Novartis 4.Merck & Co. 5.Biogen Competitors 6.Teva pharmaceuticals
doc_138396820.docx